ORIGINAL ARTICLE
Short-term prognosis of childhood hepatoblastoma in relation to ERCC1 C118T single nucleotide polymorphism and VEGF expression
1
Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China
Submission date: 2018-12-21
Acceptance date: 2019-10-26
Publication date: 2020-03-06
Pol J Pathol 2019;70(4):304-310
KEYWORDS
TOPICS
ABSTRACT
To evaluate the short-term prognosis of pediatric hepatoblastoma (HB) in relation to excision repair cross-complementation gene 1 (ERCC1) C118T single nucleotide polymorphism (SNP) and VEGF expression.
ERCC1 C118T SNP and VEGF expression were detected and investigated in 31 children with HB undergoing platinum-based chemotherapy, to analyze their relationship with short-term pediatric HB prognosis.
CC (38.7%; 12/31), CT (35.5%; 11/31), and TT (25.8%; 8/31) ERCC1 C118T mutation types were identified. The Kaplan-Meier survival curve analysis showed that the CC group had a better short-term prognosis than the CT + TT group (p = 0.010). VEGF was overexpressed in 14 cases (45.2%) and underexpressed in 17 cases (54.8%). The Kaplan-Meier survival curve analysis showed that the high VEGF expression group showed poorer short-term prognosis than the lower VEGF expression group (p = 0.004).
In this study, ERCC1 C118T SNP in children with HB was mainly found to be mutant type CT + TT. Compared to wild type CC, children with the mutant type CT + TT exhibited better treatment efficacy and remission with platinum-based chemotherapy as well as better survival rates. Moreover, the short-term prognosis of children with low VEGF expression was better than in those with high expression.
ERCC1 C118T SNP and VEGF expression were detected and investigated in 31 children with HB undergoing platinum-based chemotherapy, to analyze their relationship with short-term pediatric HB prognosis.
CC (38.7%; 12/31), CT (35.5%; 11/31), and TT (25.8%; 8/31) ERCC1 C118T mutation types were identified. The Kaplan-Meier survival curve analysis showed that the CC group had a better short-term prognosis than the CT + TT group (p = 0.010). VEGF was overexpressed in 14 cases (45.2%) and underexpressed in 17 cases (54.8%). The Kaplan-Meier survival curve analysis showed that the high VEGF expression group showed poorer short-term prognosis than the lower VEGF expression group (p = 0.004).
In this study, ERCC1 C118T SNP in children with HB was mainly found to be mutant type CT + TT. Compared to wild type CC, children with the mutant type CT + TT exhibited better treatment efficacy and remission with platinum-based chemotherapy as well as better survival rates. Moreover, the short-term prognosis of children with low VEGF expression was better than in those with high expression.
REFERENCES (36)
1.
Czauderna P, Lopezterrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26: 19-28.
2.
Allan BJ, Parikh PP, Diaz S, et al. Predictors of survival and incidence of hepatoblastoma in the paediatric population. HPB (Oxford) 2013; 15: 741-746.
3.
Hiyama E, Hishiki T, Watanabe K, et al. Mortality and morbidity in primarily resected hepatoblastomas in Japan: Experience of the JPLT (Japanese Study Group for Pediatric Liver Tumor) trials. J Pediatr Surg 2015; 50: 2098-2101.
4.
Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma – results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000; 36: 1418-1425.
5.
Ismail H, Broniszczak D, Kaliciñski P, et al. Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years. J Pediatr Surg 2012; 47: 1331-1339.
6.
Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children’s Oncology Group. J Clin Oncol 2011; 29: 3301-3306.
7.
Park CH, Bessho T, Matsunaga T, et al. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem 1995; 270: 22657-22660.
8.
Deng Q, Yang H, Lin Y, et al. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China. Int J Clin Exp Pathol 2014; 7: 8312-8321.
9.
Xu Q, Ding YY, Song LX, et al. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer. Genet Mol Res 2015; 14: 7241-7247.
10.
Zhang YY, Gu KS, Wu HY, et al. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. Genet Mol Res 2015; 14: 15921-15929.
11.
Yu X, Xiao H, Zhao B, et al. DNA repair gene ERCC1 C118T polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a Chinese population. Thorac Cancer 2015; 6: 741-748.
12.
He MG, Zheng K, Tan D, et al. Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer. Genet Mol Res 2016; 15: gmr7879.
13.
Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005; 11: 6212-6217.
14.
Costache MI, Ioana M, Iordache S, et al. VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature. Rom J Intern Med 2015; 53: 199-208.
15.
Hsieh MC, Hsu HT, Hsiao PC, et al. Role of VEGF-C Gene Polymorphisms in Susceptibility to Hepatocellular Carcinoma and Its Pathological Development. J Clin Lab Anal 2014; 28: 237-244.
16.
Sun XY, Wu ZD, Liao XF, et al. Tumor angiogenesis and its clinical significance in pediatric malignant liver tumor. World J Gastroenterol 2005; 11: 741-743.
17.
Aronson DC, Meyers RL. Malignant tumors of the liver in children. Semin Pediatr Surg 2016; 25: 265-275.
18.
Kapadia RN, Zeidman MJ, Burjonrappa S. Advanced Hepatoblastoma: A Review of Current Management Strategies. Adv Res Gastroentero Hepatol 2015; 1: 555551.
19.
Cai S, Han K. Research on expression and importance of p53, p16 and VEGF-C in cervical cancer. J Gynecol Obstet Biol Reprod (Paris) 2015; 44: 639-645.
20.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
21.
Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma: an update. Curr Opin Pediatr 2014; 26: 362-369.
22.
Hiyama E. Pediatric hepatoblastoma: diagnosis and treatment. Transl Pediatr 2014; 3: 293-299.
23.
Czauderna P. Hepatoblastoma throughout SIOPEL trials – clinical lessons learnt. Front Biosci (Elite Ed) 2012; 4: 470-479.
24.
Perilongo G, Malogolowkin M, Feusner J. Hepatoblastoma clinical research: lessons learned and future challenges. Pediatr Blood Cancer 2012; 59: 818-821.
25.
von Schweinitz D. Hepatoblastoma: recent developments in research and treatment. Semin Pediatr Surg 2012; 21: 21-30.
26.
Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000; 18: 2665-2675.
27.
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-378.
28.
Usanova S, Piée-Staffa A, Sied U, et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010; 9: 475-489.
29.
Gazdar AF. DNA repair and survival in lung cancer – the two faces of Janus. N Engl J Med 2007; 356: 771-773.
30.
Sancar A, Reardon JT. Nucleotide excision repair in E. coli and man. Adv Protein Chem 2004; 69: 43-71.
31.
Yanlong Y, Lei X. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 2014; 35: 2905-2921.
32.
Yin M, Yan J, Martinez-Balibrea E, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 2011; 17: 1632-1640.
33.
Mccrudden KW, Hopkins B, Frischer J, et al. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg 2003; 38: 308-314.
34.
Dorff TB, Longmate JA, Pal SK, et al. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer 2017; 123: 4566-4573.
35.
Diaz-Beveridge R, Bruixola G, Lorente D, et al. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clin Transl Oncol 2018; 20: 322-329.
36.
Marsh AM, Lo L, Cohen RA, et al. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. Pediatr Blood Cancer 2012; 59: 939-940.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
